Discover the new educational ERN Rare-Liver webinar series launched in November 2020.
In this sixth webinar on PBC therapy, which took place on 13 April 2021, Professor Pietro Invernizzi moderated a discussion with Dr Marco Carbone, Professor Frederik Nevens and Dr Christophe Corpechot about the risk stratification and best therapeutic strategy for PBC, the use of obeticholic acid as a second line therapy and the role of fibrates and other PPAR modulators to treat PBC, respectively.
- General Practitioners
- Health care professionals
1. Risk stratification and best therapeutic strategy
2. Registered second line: Obeticholic acid (including long-term data)
3. Fibrates and compounds in study
|Dr Invernizzi is Professor of Gastroenterology at the University of Milano-Bicocca and Director of Division of Gastroenterology and Center for Autoimmune Liver Diseases, European Reference Network-Liver Centre San Gerardo University Hospital, Monza. His areas of scientific expertise are on rare autoimmune liver diseases such as primary biliary cirrhosis (PBC), primary sclerosing cholangitis (PSC), autoimmune hepatitis (AIH), and their overlaps. More recently he extended his interests on the biliary and neuroendocrine tumours.|
|Dr Carbone is Senior Lecture at the University of Milano-Bicocca and Honorary Consultant Hepatologist at the European Reference Network-Liver Centre San Gerardo University Hospital, Monza where he is the clinical lead of the cholestatic liver disease programme. His research interest mainly relates to biomarker discovery in cholestatic liver diseases, that can inform mechanistic understanding, health care decisions, and the design of innovative clinical trials.|
|Frederik Nevens is Professor of Medicine at the KU Leuven, Belgium. He is senior Hepatologist and the Medical Director of the Liver Transplant program at the University Hospitals Leuven (Belgium). He is currently the coordinator of the courses of Digestive Diseases at the University of Leuven (KUL). He is author/co-author of > 800 publications (web of science) with a sum of times cited of 20 000 and he was the presenter of >500 lectures at national and international scientific meetings (including EASL, AASLD, Best of EASL speaker and Gastro Update Europe).|
|Dr Christophe Corpechot has been practicing medicine as a hepatologist at the Saint-Antoine Hospital in Paris, France, for over 20 years. He is a specialist in autoimmune and cholestatic liver diseases and heads the French reference center for inflammatory biliary diseases and autoimmune hepatitis MIVB-H within the healthcare network for rare liver diseases FILFOIE.|